Wellington Management Group LLP Purchases 854,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Wellington Management Group LLP increased its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 352.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,096,744 shares of the company's stock after purchasing an additional 854,346 shares during the period. Wellington Management Group LLP owned approximately 1.42% of Replimune Group worth $13,282,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Sterling Capital Management LLC boosted its position in Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares during the period. Tower Research Capital LLC TRC boosted its position in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after buying an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd boosted its position in Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Replimune Group during the 4th quarter valued at $117,000. Finally, Quantinno Capital Management LP purchased a new stake in Replimune Group during the 4th quarter valued at $127,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on REPL. HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler raised their target price on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $19.75.

Replimune Group Stock Up 6.5%

Shares of Replimune Group stock traded up $0.63 during trading on Friday, hitting $10.38. The company's stock had a trading volume of 1,927,195 shares, compared to its average volume of 931,232. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company has a fifty day simple moving average of $8.38 and a two-hundred day simple moving average of $11.04. The company has a market capitalization of $800.16 million, a PE ratio of -3.38 and a beta of 0.68. Replimune Group, Inc. has a 52 week low of $6.44 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the company posted ($0.25) EPS. Equities research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Andrew Schwendenman sold 3,287 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the completion of the transaction, the chief accounting officer now directly owns 68,284 shares in the company, valued at $549,686.20. This trade represents a 4.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now owns 146,933 shares of the company's stock, valued at approximately $1,184,279.98. The trade was a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 in the last three months. 8.80% of the stock is owned by corporate insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.